MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Vasomotor Symptoms in Postmenopausal
Conditions
Moderate to Severe Vasomotor Symptoms in Postmenopausal, Women
Trial Timeline
Dec 17, 2009 → Jul 30, 2010
NCT ID
NCT01015677About MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg is a phase 2 stage product being developed by Merck for Moderate to Severe Vasomotor Symptoms in Postmenopausal. The current trial status is terminated. This product is registered under clinical trial identifier NCT01015677. Target conditions include Moderate to Severe Vasomotor Symptoms in Postmenopausal, Women.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01015677 | Phase 2 | Terminated |
Competing Products
20 competing products in Moderate to Severe Vasomotor Symptoms in Postmenopausal